CRINETICS PHARMACEUTICALS IN CRNX
ASignal's systematic analysis rates CRNX as Neutral.
Reflects the latest available analysis · analyzed Sep 4, 2026
The case on CRNX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Exceptional year-over-year revenue growth (2336.3%)
- High cash position with $1.21B cash and low debt ($47.19M)
- Strong liquidity with current ratio of 15.57x
- Low debt-to-equity ratio (0.04x)
- Extremely overbought RSI at 92.36
- Negative MACD histogram indicating weakening momentum
- Negative operating and gross margins
- Negative free cash flow (-$248.76M)
- Extremely high valuation metrics: P/S of 213.8x, EV/Revenue of 186.25x
- Negative ROE (-42.45%) and ROA (-26.28%)
See the full verdict on CRNX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CRNX
Most investors never get a second opinion, let alone several. ASignal runs CRNX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.